Akari Reports Breakthrough Preclinical Data for AKTX-101 in KRAS-Mutated Pancreatic Cancer, Stock Surges 50%
Key Insights
Akari Therapeutics' AKTX-101 combined with Adagrasib showed synergistic cell-killing in KRAS (search)-mutant pancreatic cancer (search) models, while older TROP2 (search) ADCs demonstrated antagonism.
AKTX-101 is a TROP2 (search)-targeting ADC powered by the company's proprietary PH1 RNA spliceosome-modulating payload, with IND-enabling studies underway.
Initiation of a Phase 1 first-in-human clinical trial for AKTX-101 is expected by mid-2027.
Akari Therapeutics Plc (AKTX) saw its shares surge nearly 50% on Thursday after the oncology biotechnology company reported breakthrough preclinical data demonstrating synergistic activity of its lead drug candidate AKTX-101 with KRAS (search) inhibition in KRAS-mutated pancreatic cancer (search) models.
The findings position AKTX-101 as a potentially differentiated TROP2 (search)-targeting antibody-drug conjugate (ADC) in a challenging tumor type with significant unmet medical need.
Preclinical Synergy with KRAS (search) Inhibition
In laboratory studies, AKTX-101 combined with Bristol Myers Squibb (search)'s approved drug Adagrasib demonstrated synergistic cell-killing in KRAS (search)-mutant cell lines driven by both G12C and G12D mutations. This dual-mutation activity is notable given the prevalence of these alterations in pancreatic ductal adenocarcinoma.
In contrast, older topoisomerase I-targeting TROP2 (search) ADC drugs did not work well with Adagrasib and even showed antagonism, meaning the combination was less effective than either agent alone. This finding underscores the potential differentiation of AKTX-101's mechanism of action.
AKTX-101 is powered by the company's proprietary PH1 RNA spliceosome-modulating payload, which distinguishes it from conventional topoisomerase I inhibitor-based TROP2 (search) ADCs.
Clinical Development Timeline
Akari has initiated IND-enabling studies for AKTX-101, and initiation of a Phase 1 first-in-human clinical trial is expected by mid-2027. The company has not yet disclosed specific trial design details or target enrollment figures for the planned study.
Corporate Developments
To maintain its Nasdaq listing, Akari implemented a 1-for-40 reverse stock split on March 31, 2026. The company's stock closed Thursday's trading at $5.14, reflecting a gain of 49.85% on the session.
The preclinical results arrive at a time of growing interest in KRAS (search)-targeted combination strategies, particularly in pancreatic cancer (search), where KRAS mutations are present in approximately 90% of cases and effective therapeutic options remain limited.